Erste Asset Management GmbH Buys Shares of 116,850 Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Erste Asset Management GmbH bought a new stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 116,850 shares of the biopharmaceutical company’s stock, valued at approximately $1,251,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. purchased a new stake in Amicus Therapeutics during the 2nd quarter worth approximately $8,386,000. M&G Plc grew its holdings in shares of Amicus Therapeutics by 12.4% during the second quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock valued at $7,485,000 after buying an additional 82,728 shares during the last quarter. Fiera Capital Corp increased its position in shares of Amicus Therapeutics by 1.1% in the 2nd quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after acquiring an additional 58,113 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its stake in Amicus Therapeutics by 51.5% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 222,934 shares of the biopharmaceutical company’s stock worth $2,381,000 after acquiring an additional 75,807 shares during the last quarter. Finally, Mutual of America Capital Management LLC lifted its position in Amicus Therapeutics by 24.2% during the 2nd quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after acquiring an additional 48,802 shares during the period.

Insider Activity

In related news, CEO Bradley L. Campbell sold 7,500 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $11.46, for a total transaction of $85,950.00. Following the sale, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $10,161,054.84. This trade represents a 0.84 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold 30,401 shares of company stock valued at $339,363 in the last three months. 2.20% of the stock is currently owned by company insiders.

Amicus Therapeutics Stock Down 1.7 %

Shares of NASDAQ:FOLD opened at $9.79 on Wednesday. Amicus Therapeutics, Inc. has a 1-year low of $9.02 and a 1-year high of $14.57. The stock has a market cap of $2.93 billion, a P/E ratio of -28.79 and a beta of 0.60. The firm has a fifty day moving average price of $10.68 and a 200 day moving average price of $10.61. The company has a debt-to-equity ratio of 2.18, a current ratio of 3.15 and a quick ratio of 2.42.

Analyst Ratings Changes

A number of brokerages have recently weighed in on FOLD. Guggenheim increased their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Jefferies Financial Group initiated coverage on shares of Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price target for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, November 7th. JPMorgan Chase & Co. increased their price objective on shares of Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Morgan Stanley decreased their target price on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating for the company in a research report on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $17.63.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.